1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
ScinoPharm Taiwan, Ltd.

ScinoPharm Taiwan, Ltd.

1789.TW
ScinoPharm Taiwan, Ltd.TW flagTaiwan Stock Exchange
21.05
TWD
+0.20
- -
16.65BMarket Cap

Total Valuation

ScinoPharm Taiwan, Ltd. carries a market capitalization of 16.65B, placing it among publicly traded companies globally. Its enterprise value stands at 11.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap16.65B
Enterprise Value11.94B

Share Statistics

ScinoPharm Taiwan, Ltd. currently has 790.74M shares outstanding.

Shares Outstanding790.74M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

ScinoPharm Taiwan, Ltd. trades at a trailing price-to-earnings ratio of 69.92. The price-to-sales ratio is 4.48, and the price-to-book ratio stands at 1.74.

PE Ratio69.92
PS Ratio4.48
PB Ratio1.74
P/TBV Ratio1.40
P/FCF Ratio16.34
P/OCF Ratio25.72

Enterprise Valuation

On an enterprise value basis, ScinoPharm Taiwan, Ltd. trades at an EV/EBITDA multiple of 54.82 and an EV/FCF ratio of 13.53. The EV/Sales ratio of 3.74 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 54.82 provides insight into valuation relative to core operating earnings.

EV / Sales3.74
EV / EBITDA54.82
EV / EBIT54.82
EV / FCF13.53

Financial Position

ScinoPharm Taiwan, Ltd. maintains a current ratio of 5.34, meaning it holds 5.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.04, indicating elevated leverage, while an interest coverage ratio of 25.88 demonstrates strong ability to service its debt obligations.

Current Ratio5.34
Quick Ratio2.92
Debt / Equity7.04
Debt / EBITDA3.32
Interest Coverage25.88

Financial Efficiency

ScinoPharm Taiwan, Ltd. posts a return on equity of 2.48 and a return on invested capital of 1.60.

Return on Equity (ROE)2.48
Return on Assets (ROA)1.71
Return on Invested Capital (ROIC)1.60
Return on Capital Employed (ROCE)2.37
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.07

Taxes

Over the trailing twelve months, ScinoPharm Taiwan, Ltd. has paid 47.29M in income taxes, reflecting an effective tax rate of 18.77.

Income Tax47.29M
Effective Tax Rate18.77

Stock Price Statistics

ScinoPharm Taiwan, Ltd.'s stock has gained approximately 25.29762% over the past 52 weeks. The 50-day moving average sits at 19.98, while the 200-day moving average is 20.13.

Beta (5Y)N/A
52-Week Price Change25.29762%
50-Day Moving Average19.98
200-Day Moving Average20.13
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, ScinoPharm Taiwan, Ltd. generated 3.19B in revenue and converted that into 204.67M in net income, yielding earnings per share of 0.24. EBITDA reached 217.85M, while operating income came in at 217.85M.

Revenue3.19B
Gross Profit1.20B
Operating Income217.85M
Pretax Income251.96M
Net Income204.67M
EBITDA217.85M
EBIT217.85M
Earnings Per Share (EPS)0.24

Balance Sheet

ScinoPharm Taiwan, Ltd. holds 3.09B in cash and equivalents against 723.37M in total debt, resulting in a net debt position of -3.00B. Total book value stands at 8.22B, with working capital of 4.60B providing operational flexibility.

Cash & Cash Equivalents3.09B
Total Debt723.37M
Net Debt-3.00B
Equity (Book Value)8.22B
Book Value Per Share9.76
Working Capital4.60B

Cash Flow

ScinoPharm Taiwan, Ltd. produced 556.34M in operating cash flow over the past twelve months. After subtracting -319.23M in capital expenditures, free cash flow totaled 237.11M - equivalent to 0.28 per share.

Operating Cash Flow556.34M
Capital Expenditures-319.23M
Free Cash Flow237.11M
FCF Per Share0.28

Margins

ScinoPharm Taiwan, Ltd. operates with a gross margin of 37.68, reflecting its pricing power and cost economics. The operating margin of 6.82 and net profit margin of 6.41 provide insight into operational efficiency.

Gross Margin37.68
Operating Margin6.82
Pretax Margin7.89
Profit Margin6.41
EBITDA Margin6.82

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield1.17
FCF Yield6.12

Stock Splits

ScinoPharm Taiwan, Ltd.'s most recent stock split took place on August 10, 2017 with a 25:26 split ratio.

Last Split Date8/10/2017
Split Ratio25:26

Scores

ScinoPharm Taiwan, Ltd. posts an Altman Z-Score of 5.89, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.89